[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/main/docs/Risk/index.md) >> Individual ID:PBN__Risk_1589 

# __Lack of effective pharmaceutical response__

## Articles mentionning the risk

* [The Role of Architecture and Urbanism in Preventing Pandemics](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_140.md)

## Category to which it belongs

* [Inadequate resources, staff, facilities, training, coordination, and preparedness contribute to the inefficient and ineffective response to various challenges and needs.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_78.md)

## Closest similar item

* [Impact on healthcare systems and pharmaceutical industry](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1478.md)
* [Ineffective non-pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2684.md)
* [Inefficient medication delivery](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1151.md)
* [Insufficient non-pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1590.md)
* [Lack of access to pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1849.md)
* [Lack of accessibility of pharmaceutical interventions in developing countries](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_727.md)
* [Lack of drug therapy options](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1139.md)
* [Lack of effective drugs](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1794.md)
* [Lack of effective treatment](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2164.md)
* [Lack of novel treatment options](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2165.md)

## Description of the risk

Ineffective vaccines and long development time for new vaccines and antibiotics

## Is the risk affecting GBN scales

* [No](https://github.com/mm80843/T3.5/blob/pages/ISO/PBN__ISO_Scale_0.md)

## Mitigations of this risk

* [Improve surveillance for drug resistance, invest in vaccine development infrastructure](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_2134.md)

## Name of the risk

Delayed response and increased mortality rates

## People affected by this risk

* [General population](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_9.md)
* [Healthcare systems](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_193.md)

## Stakeholders who can mitigate this risk

* [None](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_627.md)

## Technologies linked to the risk

* [Drug resistance surveillance technology](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_915.md)
* [Vaccine development technology](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_916.md)

## Type of impact of the risk (according to ISO37100)

* [Health and care](https://github.com/mm80843/T3.5/blob/pages/ISO/PBN__ISO_Purpose_0.md)

## Type of purpose of the risk (according to ISO37100)

* [Resilience](https://github.com/mm80843/T3.5/blob/pages/ISO/PBN__ISO_Impact_2.md)

## Type of the risk

* [Physical](https://github.com/mm80843/T3.5/blob/pages/RiskHealth/PBN__RiskHealth_0.md)

## Property: has_RiskType

* [Technological](https://github.com/mm80843/T3.5/blob/pages/RiskType/PBN__RiskType_5.md)

